Receptors, Purinergic P2Y12
-
Subject Areas on Research
-
A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.
-
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
-
Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?
-
Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
-
Antiplatelet treatment of cardiovascular disease: a translational research perspective.
-
Aspirin and clopidogrel resistance: consideration and management.
-
Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
-
Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina.
-
Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists.
-
Clopidogrel resistance?
-
Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.
-
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
-
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.
-
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
-
Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents.
-
Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl).
-
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
-
Elinogrel: pharmacological principles, preclinical and early phase clinical testing.
-
Ether lipid metabolism by AADACL1 regulates platelet function and thrombosis.
-
Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures.
-
G-protein-coupled receptors as signaling targets for antiplatelet therapy.
-
G-protein-coupled receptors signaling pathways in new antiplatelet drug development.
-
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).
-
Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study.
-
High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?
-
Immunity to thrombotic events is achievable if we stop the guessing game: is this the major hidden message from GRAVITAS?
-
Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.
-
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
-
Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy?
-
Is clopidogrel as the P2Y12 inhibitor a wise choice for long-term monotherapy in patients undergoing stenting?
-
Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial.
-
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
-
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
-
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
-
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
-
Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists.
-
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
-
Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies.
-
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
-
Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y₁₂ inhibitor therapeutic window.
-
Platelet-Mediated Thrombosis: From Bench to Bedside.
-
Prasugrel.
-
Precatheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry®.
-
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
-
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
-
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
-
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
-
Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.
-
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
-
Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
-
The Dogged Search for Cryptic Effects of Ticagrelor: Wishful Thinking or Real Benefits Beyond P2Y12 Inhibition?
-
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
-
Ticagrelor for the treatment of arterial thrombosis.